1 / 34

Management of Tuberculosis: A Surgical Perspective

Management of Tuberculosis: A Surgical Perspective. Alfred Lardizabal, MD Associate Professor Division of Pulmonary and Critical Care Medicine UMDNJ-NJ Medical School and Global Tuberculosis Institute. Case #1- History. WW, 38 year old male April 1999, AFB(+)

Télécharger la présentation

Management of Tuberculosis: A Surgical Perspective

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Management of Tuberculosis: A Surgical Perspective Alfred Lardizabal, MD Associate Professor Division of Pulmonary and Critical Care Medicine UMDNJ-NJ Medical School and Global Tuberculosis Institute

  2. Case #1- History • WW, 38 year old male • April 1999, AFB(+) • Treatment with IRZE (self-administered) • July 1999: AFB 2+ • Referred by the private MD in July 1999 for the management of pulmonary tuberculosis

  3. July 15, 1999

  4. Case #1 – Culture Results • By August 1999, culture was identified as M. tuberculosis; resistant to I,R,Z,E • Specimen sent for 2nd line drug susceptibility testing • I,R,Z,E continued during interim period

  5. Case #1 – Susceptibility Results • CDC • Resistant: RIF/RBT; INH; PZA • Sensitive: SM / CM / AK; EMB; CIP; CS; ETA • NJMRC • Resistant: RIF/RBT; INH; PZA • Sensitive: SM / CM / AK; EMB; CS; PAS; CIP/OFL; CLA; CLO

  6. Case #1 – Subsequent Regimen • Treatment regimen changed by 8-24-99: • Capreomycin 1 gm IM 5 X/week • Levofloxacin 500 mg OD • Cycloserine 750 mg OD • Clofazimine 300 mg OD • Clarithromycin 500 mg BID

  7. Sputum Smear & Culture - 1 • 7-13-99 AFB 2+ M.tb • 8-24-99* AFB TNC M.tb • 9-21-99 AFB <1+ M.tb • 10-19-99 neg neg • 11-16-99 neg neg • 12-14-99 neg neg • 1-18-00 neg neg

  8. September 21, 1999

  9. January 10, 2000

  10. Sputum Smear & Culture - 2 • 3-7-00 AFB neg M.tb • 4-17-00* neg neg • 4-28-00 neg M.tb • 4-29-00 neg M.tb • 5-1-00 neg M.tb • 6-1-01 neg M. tb *capreomycin was discontinued after 8 mos.

  11. Pre-Op • By June 2000, pt. continued to have positive sputum cultures (AFB-) • CT Chest was requested • Preparation and evaluation for adjunctive surgery was started • FOB/Bronchial biopsy Sept 2000 • RUL bronchus clean

  12. June 2000

  13. Post-Op Medical Management - 1 • NJMRC Sept 2000 • Resistant: RIF/RBT; INH; PZA • Intermediate: CLO; CIP; CLA • Sensitive: SM / CM / AK; CS; PAS; EMB; ETA • Treatment Oct 2000: EMB; SM; PAS; CS • Discontinued CLA, CLO, LFX

  14. Sputum Smear & Culture - 3 • 8-8-00 neg MTBC • 9-1-00 +1 MTBC • 10-3-00 +1 MTBC • 12-7-00 +1 MTBC • 1-5-01 +1 MTBC • 6-3-01 +1 MTBC

  15. May 2001

  16. Post-Op Medical Management - 2 • Patient was admitted for a right upper lobectomy 6-10-01 • Discharged home on EMB, PAS, SM, CS • Persistent GI complaints prompted D/C of PAS and changed to gatifloxacin by 7-1-01 • Post-surgery patient remained smear and culture negative

  17. June 17, 2001

  18. August 20, 2001

  19. October 1, 2002

  20. Post-Op Medical Management - 3 • CM continued until Feb 2002 (15 months) • EMB, CS, GFX continued until Dec 2002 (18 months post-surgery) remaining smear and culture negative

  21. Follow-Up - 1 • On the January 2004 follow-up patient had no complaints. He gained 20 lbs. since the last visit 6 months prior • Chest x-ray and sputum cultures have been negative up to this point

  22. January 2004

  23. January 2004

  24. Follow-Up - 2 • Jan 2004 Sputum: AFB1+: MTBC • Started EMB, CS, PAS, CM, linezolid (Zyvox) • NJMRC: • Resistant: INH, RIF, PZA, LFX • Sensitive: PZA, EMB, SM/CM/ ETA, CS, PAS • CM stopped after 8 months • Sputum conversion by March 2004 • Remained sputum negative

  25. July 2004

  26. August 2004

  27. Follow-Up Regimen • Current regimen started 2/04; discontinued 24 months after sputum culture conversion • CM – 7 mos. • Remains smear and culture negative >2 years after treatment completion EMB CS LIN 24 mos

  28. Case #2 - History • 53 year old Hispanic female with a history of breast carcinoma • Has had chemotherapy and radiation therapy after total mastectomy of her right breast the last cycle of chemotherapy was given in May 2007 • On follow-up, PET/CT revealed positive uptake in the lung and colon

  29. Case #2 – Chest X-ray September 2007

  30. September 2007

  31. Case #2 – Surgical Intervention • Wedge resection of the right lung nodule as well as a colonoscopy was planned • Lung tissue from the wedge resection was AFB+ • Biopsy of the colon was also AFB+

  32. Case #2 – Post-Op Treatment • Treatment with RIPE started • Culture of lung tissue and sputum positive for M. tuberculosis • DST: sensitive to RIPE,SM • Is currently on therapy and responding very well

More Related